Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:REPH

Recro Pharma (REPH) Stock Price, News & Analysis

Recro Pharma logo

About Recro Pharma Stock (NASDAQ:REPH)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.47
$2.11
52-Week Range
N/A
Volume
141,800 shs
Average Volume
126,298 shs
Market Capitalization
$117.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive REPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Recro Pharma and its competitors with MarketBeat's FREE daily newsletter.

REPH Stock News Headlines

Fuji Pharma Co. Ltd.
Here's what Wall Street expects from Recro Pharma's earnings report
I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
What Wall Street expects from Recro Pharma's earnings
Mankind Pharma Ltd (MNKI)
See More Headlines

REPH Stock Analysis - Frequently Asked Questions

Recro Pharma, Inc. (NASDAQ:REPH) posted its earnings results on Tuesday, March, 1st. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.03. Recro Pharma had a negative trailing twelve-month return on equity of 56.66% and a negative net margin of 15.15%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Recro Pharma investors own include Corbus Pharmaceuticals (CRBP), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), SCYNEXIS (SCYX), Gilead Sciences (GILD) and Bristol Myers Squibb (BMY).

Company Calendar

Last Earnings
3/01/2022
Today
7/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:REPH
CIK
1588972
Employees
185
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.31)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$11.37 million
Net Margins
-15.15%
Pretax Margin
-15.09%
Return on Equity
-56.66%
Return on Assets
-11.14%

Debt

Debt-to-Equity Ratio
2.27
Current Ratio
3.24
Quick Ratio
2.74

Sales & Book Value

Annual Sales
$75.36 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.90 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
56,424,000
Free Float
48,412,000
Market Cap
$117.93 million
Optionable
Optionable
Beta
1.08
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:REPH) was last updated on 7/14/2025 by MarketBeat.com Staff
From Our Partners